Abuse Potential of Sativex

NCT01323569 | Completed Phase 1

• 1 other identifier: GWCP0605
• Study Type: interventional
• Target: 58
• Locations: 1 country
• Sites: 1

Brief Summary

This crossover study with six treatment sessions is to evaluate the abuse potential of three doses of Sativex as compared to Marinol and placebo, in subjects with a history of recreational marijuana use.

Conditions

Evaluation of Abuse Potential of Sativex

Keywords

Sativex; Cannabinoids; Abuse potential; Addiction

Outcome Measures

Primary Outcomes (3)

• Comparison of Subjective Drug Value (SDV)(Balance of effects) between Marinol and Sativex

  Mean difference in Mean peak effect (Emax) between: Marinol 20 mg vs Sativex 21.6 mg; Marinol 20 mg vs Sativex 43.2 mg; Marinol 40 mg vs Sativex 43.2 mg.

  Recorded at 6, 12 and 24 hours during each study arm

• Comparison of Bipolar Drug Liking VAS (Balance of effects) between Marinol and Sativex

  Mean difference in Mean peak effect (Emax) between: Marinol 20 mg vs Sativex 21.6 mg; Marinol 20 mg vs Sativex 43.2 mg; Marinol 40 mg vs Sativex 43.2 mg.

  Recorded at 12 and 24 hours during each study arm

• Comparison of Addiction Research Centre Inventory (ARCI) MBG (Positive effects) between Marinol and Sativex

  Mean difference in Mean peak effect (Emax) between: Marinol 20 mg vs Sativex 21.6 mg; Marinol 20 mg vs Sativex 43.2 mg; Marinol 40 mg vs Sativex 43.2 mg.

  Recorded at 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours during each study arm

Secondary Outcomes (7)

• Comparison of Balance of Effects VASs between Marinol and Sativex

  Recorded at 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours during each study arm

• Comparison of Positive Effects VASs between Marinol and Sativex

  Recorded at 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours during each study arm

• Comparison of Cannabinoid Effects between Marinol and Sativex

  Recorded at 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours during each study arm

• Comparison of Negative Effects Scores between Marinol and Sativex

  Recordedat 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours during each study arm

• Comparison of Other Effects Scores between Marinol and Sativex

  Recorded pre-dose and at 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours during each study arm

Study Arms (6)

Placebo

PLACEBO COMPARATOR

Drug: Placebo

Sativex 4 sprays

EXPERIMENTAL

Drug: Sativex

Sativex 8 sprays

EXPERIMENTAL

Drug: Sativex

Sativex 16 sprays

EXPERIMENTAL

Drug: Sativex

Marinol low dose

ACTIVE COMPARATOR

Drug: Marinol

Marinol high dose

ACTIVE COMPARATOR

Drug: Marinol

Interventions

Sativex DRUG

Sativex dose level 1: 10.8 mg THC/10 mg CBD (4 sprays) + 12 placebo sprays + 4 placebo capsules.

Sativex 4 sprays

Placebo DRUG

16 placebo sprays and 4 placebo capsules

Placebo

Marinol DRUG

Marinol dose level 1: 20 mg THC (2 marinol capsules) + 2 placebo capsules + 16 placebo sprays

Marinol low dose

Eligibility Criteria

• Age: 19 Years - 45 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy male and female subjects, 19 to 45 years of age, inclusive.
• Current recreational marijuana users, defined as the use of smoked marijuana, hashish, or oral THC, at least once a week for the 3 months prior to screening and, on at least one occasion, four times in a given week in the 3 months prior to screening.
• Body mass index within the range of 19 to 30 kg/m2 inclusive and a minimum weight of at least 50 kg at screening.
• Free of any clinically significant abnormality, assessed at screening, on the basis of medical history, vital signs, physical examination, 12-lead ECG, and clinical laboratory tests, including haematology, clinical chemistry, urinalysis, and serology, as judged by the investigator or designee.
• A positive urine THC drug screen at screening and qualification, which was confirmed by quantitative analysis; the level must have been at least 50 ng of THC/mL.
• A negative urine drug screen for cocaine, opiates, amphetamine, and benzodiazepines upon admission to the screening, qualification session, or treatment sessions. Subjects who had a positive urine drug screen upon presentation to a study visit could have been rescheduled for another session at the discretion of the investigator.
• All female subjects were required to have a negative serum pregnancy test at screening and a negative urine pregnancy test prior to the qualification session and to each drug treatment session.
• Subjects with reproductive potential could be entered into the study if they had been using and were willing to continue to use two methods of contraception for the duration of the study. These methods included male condom for men in addition to an oral contraceptive, contraceptive implant or injection, intrauterine device, diaphragm, or a contraceptive sponge for women. Adequate protection, as defined above, had to have been used for at least 1 month prior to screening for all, with the exception of oral contraceptives, which should have been used for at least 3 months prior to screening. These methods had to be continually used for 30 days after the end of the study. Subjects that had been surgically sterilized (tubal ligation, hysterectomy, or vasectomy) or had been post-menopausal for at least 2 years (by history) were not considered to be of reproductive potential.
• Subjects had to pass a qualification session.
• Must have understood and provided written informed consent, prior to initiation of any protocol-specific procedures.
• Subjects were able to comply with study procedures.
• Negative breath alcohol test. Subjects who had a positive breath alcohol test could have been rescheduled at the discretion of the investigator.

You may not qualify if:

• History or presence of drug or alcohol dependence (excluding nicotine and caffeine), including subjects who had ever been in a drug rehabilitation program.
• Clinically important impairment or dysfunction of any body system, including, but not limited to, the following: cardiovascular, haematological, hepatic, gastrointestinal, renal, pulmonary, or neurological, as judged by the investigator or designee.
• Any known or suspected history (including family history) of schizophrenia or other psychotic illness. Presence or history of a psychiatric disorder, organic brain disorder, or seizure disorder that was deemed clinically significant by the investigator.
• History of hypersensitivity or allergy to cannabinoids, cannabis and/or its metabolites, to the study drug excipients, or to similar compounds (propylene glycol, ethanol, peppermint, and sesame oils) or allergic reactions to any other medication.
• Consumed caffeine-containing beverages in excess of 450 mg of caffeine (e.g. 5 cups of tea or 3 cups of regular coffee or 8 cans of cola) per day in the 6 months prior to screening.
• Consumed greater than 20 cigarettes per day.
• Treatment with another investigational or non-approved drug, within 4 weeks prior to the start of qualification session dosing (Day 1).
• Donated or lost blood (\>100 mL) within the 30 days prior to screening.
• Female subjects who were pregnant or lactating or who were planning to become pregnant within 60 days of last study drug administration.
• Used prescription drugs (except oral contraceptives or sex hormone replacement), including smoked THC for medicinal purposes, within 14 days of the qualification session and for the duration of the study, unless in the opinion of the investigator (or designee), the medication received would not interfere with the study procedures or data integrity or compromise the safety of the subject.
• Used non-prescription drugs or natural health products other than acetaminophen up to 2 g per day or vitamin or mineral supplements (including mega dose vitamin therapy), within 7 days prior to the qualification session, and for the duration of the study, unless in the opinion of the investigator (or designee), the medication received would not interfere with the study procedures or data integrity or compromise the safety of the subject.
• Uncontrolled hypertension at screening that was judged as clinically significant by the investigator (or designee).
• Subjects who, in the opinion of the investigator (or designee). were not willing, able or capable of following the study schedule for any reason.
• Subjects who were positive for or were being treated for hepatitis B, hepatitis C, or human immunodeficiency virus (HIV).
• Subjects facing current or pending legal charges.

Sponsors & Collaborators

• Jazz Pharmaceuticals: lead

Study Sites (1)

DecisionLine Clinical Research Corporation

Toronto, Ontario, M5V 2T3, Canada

Location

Related Publications (1)

• Schoedel KA, Chen N, Hilliard A, White L, Stott C, Russo E, Wright S, Guy G, Romach MK, Sellers EM. A randomized, double-blind, placebo-controlled, crossover study to evaluate the subjective abuse potential and cognitive effects of nabiximols oromucosal spray in subjects with a history of recreational cannabis use. Hum Psychopharmacol. 2011 Apr;26(3):224-36. doi: 10.1002/hup.1196.

  PMID: 21671456 RESULT

MeSH Terms

Conditions

Marijuana Abuse; Behavior, Addictive

Interventions

nabiximols; Dronabinol

Condition Hierarchy (Ancestors)

Substance-Related Disorders; Chemically-Induced Disorders; Mental Disorders; Compulsive Behavior; Impulsive Behavior; Behavior

Intervention Hierarchy (Ancestors)

Cannabinoids; Terpenes; Hydrocarbons; Organic Chemicals

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: BASIC SCIENCE
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 23, 2011
• First Posted: March 25, 2011
• Study Start: February 1, 2008
• Primary Completion: June 1, 2008
• Study Completion: June 1, 2008
• Last Updated: April 10, 2023

Record last verified: 2023-04

Locations

CA (1)